A novel phosphorylcholine oligomer-grafted and folate moiety-labeled graphene oxide (GO-PCn-FA) was designed, prepared, and characterized by Fourier transform infrared spectra, nuclear magnetic resonance, Raman spectra, X-ray diffraction, X-ray photoelectron spectroscopy, scanning transmission electron microscopy, transmission electron microscopy, and atomic force microscopy. GO-PCn-FA proved to be an excellent water-soluble and pH-responsive drug carrier for the targeted delivery of doxorubicin (DOX) with a drug loading content of 21%. An in vitro cytotoxicity assay and flow cytometry analysis revealed the superior biocompatibility of GO-PCn-FA compared to normal cells, while DOX-loaded GO-PCn-FA exerted efficient eradication of tumor cells, especially of those with folate receptor expression. An in vivo test showed that GO-PCn-FA was deposited mainly in the pulmonary parenchyma after intravenous administration, and no obvious adverse effect was observed. In summary, phosphorylcholine oligomer-grafted graphene oxide was developed for targeted drug delivery with optimal biocompatibility.

Comb-like poly(acrylonitrile-co-lauric acid) (PANLA) phase change materials with low phase change temperature were synthesized via mixed solvent precipitation polymerization where acrylonitrile (AN) and dodecyl acrylate (DA) were employed as monomers. Fourier transform infrared spectroscopy (FTIR) and 13C nuclear magnetic resonance spectroscopy (13C NMR) were used to characterize the chemical structure of the resultant PANLA. Differential scanning calorimetry (DSC) and thermogravimetry analyzer (TG) were adapted to evaluate the energy storage performance and thermal reliability of PANLA materials. Thermal analysis revealed that comb-like PANLA had a good energy storage performance and cyclic stability. The crystallization temperature of PANLA was around -8 °C with a crystallization enthalpy range of 3.77~41.30 J/g which was intended to apply in an environment with a relatively low temperature.